Investigation on alterations of skin-infiltrating T cell populations and peripheral blood biomarkers upon administration of Cosentyx (secukinumab) in patients with plaque psoriasis - Investigation on alterations of skin-infiltrating T cell populations and peripheral blood biomarkers upon administration of Cosentyx (secukinumab) in patients with plaque psoriasis

Department of Dermatology, Hamamatsu University School of Medicine0 个研究点目标入组 10 人开始时间: 2016年8月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Administration of adalimumab, infliximab and etanercept within 3 months before initiation of secukinumab.2. Administration of ustekinumab, alefacept, briakinumab and efalizumab within 6 months before initiation of secukinumab.3. Administration of cyclosporine A, methotrexate, corticosteroid, cyclophosphamide, retinoid and fumaric acid ester, and treatment with PUVA therapy within 4 weeks before initiation of secukinumab.4. Phototherapy with UVA and UVB, and topical treatment with reagents possibly affecting psoriatic lesions and symptoms, including corticosteroid, vitamin D3 analogue, tacrolimus, pimecrolimus, retinoid, salicylate petrolatum, salicylate, lactate, tar, uric acid, and hydroxy acid (fruit acid), within 2 weeks before initiation of secukinumab. 5.Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.6. Pregnancy.

发起方

Department of Dermatology, Hamamatsu University School of Medicine